Table 4.
Comparison of CD133 and CD44 expression with previous studies
| CD133 | CD44 | |||
|---|---|---|---|---|
| Tumour type | Present study | Studies in literature | Present study | Studies in literature |
| Wilms tumour | 100% (7/7) | Mehrazma M et al. [17] — 87% (28/32) | 5/7 (71.4%) | Katarzyna T et al. [18] — 18/38 (47.37%) |
| Neuroblastoma | 100% (1/1) | Tong QS et al. [19] — 46.9% (15/32) | 1/1 (100%) | V. Combaret et al. [20] — 37/52 (71.12%) |
| Lymphoma | 100% (5/5) | Mehrazma M et al.[17] — 72% (22/30) | 5/5 (100%) | Mehrazma M et al. [17] — 21/30 (77%) |
| Rhabdomyosarcoma | 100% (3/3) | - | 1/2 (50%) | G Humphrey et al. [21] — 12/27 (44.44%) |
| Yolk sac tumour | 100% (3/3) | Suzuki S et al. [22] — 100% (5/5) | 2/1 (50%) | _ |
| GIST | 100% (1/1) | Chen J et al. [23]. — 95% | 0/1 (0%) | - |
| Gliomas | 52.9% (10/19) | Zhang M et al. [24] — 78.4% (98/125) | 19/19 (100%) not associated with tumour grades | - |
| Medulloblastoma | 100% (10/10) | - | 7/10 (70%) | - |